Aesthetic medicine products. L’Oréal Q3 2021: Sales up 14.9 percent LFL versus Q3 2019

Derma filler

THE WHAT? L’Oréal has announced its results for the third quarter of fiscal 2021. In the three months ended September 30, 2021, the French beauty giant reported sales growth of 13.1 percent versus 2020 figures (+14.9 percent LFL versus the same period in 2019) bringing its growth for the first nine months of the year to 18 percent LFL.

THE DETAILS All geographic zones reported growth, most notably North America where sales were up 22.9 percent. Sales in Latin America soared 15.7 percent, North Asia saw sales swell 13.2 percent, while Europe put on a respectable 7.5 percent and SAPMENA – SSA inched up 3.2 percent.

In terms of business divisions, Active Cosmetics was the star performer, with sales up 28.4 percent, while L’Oréal Luxe put on a similarly impressive 20.7 percent. Sales of Professional Products rose 10.3 percent while Consumer Products reported a more modest 3.2 percent rise.

Fat dissolving

THE WHY? Nicolas Hieronimus, Chief Executive Officer of L’Oréal, explains, “The Group’s sales increased by +9.3 percent like-for-like over two years, compared with the first nine months of 2019, with a remarkable acceleration in the third quarter. All Divisions increased their growth over two years quarter after quarter…

“As a result of our agility, relevant strategic choices and strong investment in our brands, L’Oréal continues to significantly outperform a beauty market that is gradually returning to pre-crisis levels.

“All Zones and all Divisions are growing and contributing to the Group’s well-balanced growth. The US recovery is confirmed, and mainland China has sustained strong quarterly growth over two years, despite a few upheavals in the summer. We have maintained an offensive product launch strategy, and our performance is evidence of our brands’ desirability and of consumer demand for cutting-edge innovations. While in-store sales have recovered, e-commerce continues to grow rapidly and accounts for 26.6 percent of sales.”

  Aesthetic medicine products. L’Occitane reports 11.4 percent Q2 sales growth

Aesthetic medicine products are developed and regulated to meet stringent safety and efficacy standards. They are typically administered by trained healthcare professionals such as dermatologists, plastic surgeons, and specialized nurses in clinical settings. These products aim to provide effective solutions for cosmetic enhancement, skin rejuvenation, and overall aesthetic improvement, contributing to both physical appearance and self-confidence.

Key categories of aesthetic medicine products include:

  • Injectables: This category includes products such as dermal fillers, botulinum toxins (e.g., Botox), and collagen stimulators. These injectables are used to smooth wrinkles, add volume, and improve facial contours.

  • Skin Rejuvenation Treatments: Products like chemical peels, microdermabrasion systems, and laser devices are used to improve skin texture, reduce pigmentation irregularities, and enhance overall skin tone.

  • Skincare Products: These include medical-grade cleansers, moisturizers, serums, and topical treatments containing active ingredients like retinoids, antioxidants, and growth factors. They are formulated to address specific skin concerns such as acne, aging, and hyperpigmentation.

  • Hair Restoration Products: Medical treatments and products designed to promote hair growth and treat conditions such as male and female pattern baldness.

  • Body Contouring and Fat Reduction: Devices and products used for non-surgical body sculpting, such as cryolipolysis (cool sculpting) devices and injectable lipolytics.

  • Cosmeceuticals: High-performance skincare products that bridge the gap between cosmetics and pharmaceuticals, often containing potent ingredients with proven clinical benefits.

  • Wound Care and Scar Management: Products like silicone sheets, gels, and advanced wound dressings used to improve healing and reduce the appearance of scars.